Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Researchers Debate Costs Of Clinical Trial Data Sharing At IOM Gathering

This article was originally published in The Gray Sheet

Executive Summary

The costs associated with more expansive sharing of clinical trial data for independent research would be significant, experts warned at a meeting convened by the Institute of Medicine to help inform a planned study on strategies for increasing trial data-sharing.

You may also be interested in...

Clinical Trial Transparency Gets A Boost With J&J Agreement, IOM Report

Johnson & Johnson's device and diagnostic clinical trial data is now available to independent researchers via Yale University’s Open Data Access (YODA) Project, announced the same day as an Institute of Medicine report mapping out strategies for clinical trial data-sharing.

J&J Works Toward Device Data-Sharing Agreement Following Pharma Plan

Independent researchers will be able to request access to clinical trial data for any J&J drug from clinicians at Yale’s Open Data Access Project without involvement by the company. J&J is now in discussions to set up a similar arrangement for its device and consumer products trial data.

IOM Plans Study To Facilitate Clinical Trial Data Sharing

The Institute of Medicine issued a draft framework for a study on expanding clinical trial data sharing and is seeking input from outside parties. The draft discusses how competing firms, disease advocacy groups and the media might responsibly use data shared by clinical trial sponsors.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts